CRU SHARE SCHEME TRUSTEES LIMITED

Financial Health Score: B+

Explanation: The company exhibits a robust net asset position and a stable, long-term balance sheet, which are excellent signs of structural health. However, it suffers from a chronic lack of operational liquidity and relies entirely on the broader corporate "body" to sustain its short-term obligations. This is not a sign of terminal illness—rather, it is the natural anatomy of a specialized trustee entity. The score reflects its financial stability as a holding vessel, tempered by its absolute dependence on the parent group for survival.

1. Key Vital Signs

• Net Assets (Equity): £768,602
  • Interpretation: This is the company's "bone density"—its foundational strength. The net assets are strongly positive and have remained perfectly stable across 2023, 2024, and 2025. This indicates no internal bleeding (accumulated losses) and a healthy baseline of wealth.
• Fixed Assets (Investments): £772,872
  • Interpretation: The company's primary organ. Almost all of its value is tied up in shares of its ultimate parent company, Mattelisa Limited. This represents a 15.5% stake in the parent. The investment is held at historical cost, meaning we are looking at the original "pulse" of the investment rather than current market value, which may have grown significantly.
• Net Current Liabilities: (£4,270)
  • Interpretation: This is a symptom of short-term cash anemia. The company has only £2 in current assets (debtors) but owes £4,272 to group undertakings within the year. If this were a standalone trading business, this would be a sign of acute distress. However, because the debt is owed to its parent, it functions more like an internal IV drip than a toxic debt.
• Operational Pulse (Employees/Turnover): 0
  • Interpretation: The company has zero employees and no trading revenue. It exists in a state of suspended animation, which is entirely normal for an Employee Benefit Trust (EBT) trustee company. It doesn't need to breathe on its own because the parent group provides its oxygen.

2. Diagnosis

Diagnosis: Institutional Symbiosis

The financial data reveals that CRU SHARE SCHEME TRUSTEES LIMITED is not a trading organism; it is a specialized corporate organ functioning solely to administer an employee share scheme for the Mattelisa Group.

The identical balance sheet figures across three consecutive years (2023-2025) might initially look like a flatlining ECG, but in this context, it simply means the trust has not exercised its options or suffered impairments. The company holds the "healthy tissue" (shares) on trust for senior employees. The recent lapse of options over 506 shares shows there is some natural turnover in the scheme, but the core holding remains static.

The most notable symptom is the complete absence of liquidity. With only £2 in debtors to cover £4,272 in liabilities, the company is technically insolvent on a short-term basis. However, because the creditor is the immediate parent company (Commodities Research Unit International (Holdings) Limited), this is a managed condition. The parent acts as the life-support system, ensuring the trustee can meet its minimal administrative costs without needing its own cash flow.

3. Recommendations

To maintain and improve its financial wellness, the following actions are recommended:

• Monitor the Parent's Health: The trustee's sole asset is a £772k investment in the parent company. The true health of this entity is entirely contagious with the parent—if Mattelisa Limited catches a cold, this company's net assets will develop pneumonia. Regular impairment reviews of this investment are essential to ensure the asset isn't quietly deteriorating.
• Treat the Cash Anemia Proactively: While the parent company currently covers the £4,272 liability, relying on intercompany balances for survival can be risky if group dynamics change. The parent should consider capitalizing this debt (converting it to equity) or providing a small cash injection to give the trustee a healthier current ratio.
• Vital Sign Tracking (Valuation Updates): Because the shares are held at historical cost, the balance sheet may not reflect the true "blood pressure" of the company. Obtaining regular, independent valuations of the Mattelisa Limited shares will ensure that the trustees and scheme beneficiaries understand the real-world value of the options being held or lapsed.